1. Generics Bulletin
  2. >>Business

Sandoz Stands Alone As It Completes Novartis Spinoff

Industry Giant Enters ‘New Era’ As An Independent Company After Long-Awaited Separation

 
• By Dave Wallace

Sandoz has heralded a “new era as a standalone global leader and European champion in generic and biosimilar medicines” after completing its long journey towards independence by separating from former parent company Novartis.

Rear view of businessman in suit standing at the top of steps in front of a lit doorway; fresh start concept
Sandoz is making a fresh start as a standalone company • Source: Shutterstock

Sandoz has now taken the final step in its long journey of separation from Novartis, becoming a standalone firm as it completed its spinoff from the former parent company. But as that process comes to an end, another journey is just beginning for Sandoz, as it sets out on its own as an independent global generics and biosimilars industry leader.

Key Takeaways:

  • Sandoz is now a standalone company, having formally been spun off from Novartis

  • Today, October 4, is the first trading day for Sandoz on the SIX Swiss Exchange

  • Some links between the two firms will remain,

The firm heralded a “new era as a standalone global leader and European champion in generic and biosimilar medicines” as it confirmed that the spinoff had now taken

More from Strategy

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

More from Business

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.